When to stop immunotherapy for advanced melanoma: the emulated target trialsResearch in context by Mathilde Amiot, Laurent Mortier, Stéphane Dalle, Olivier Dereure, Sophie Dalac, Caroline Dutriaux, Marie-Thérèse Leccia, Eve Maubec, Jean-Philippe Arnault, Florence Brunet-Possenti, Julie De Quatrebarbes, Florence Granel-Brocard, Caroline Gaudy-Marqueste, Cecile Pages, Pierre-Emmanuel Stoebner, Philippe Saiag, Thierry Lesimple, Alain Dupuy, Delphine Legoupil, Henri Montaudié, Bastien Oriano, Celeste Lebbe, Raphael Porcher

Subjects: “…Advanced melanoma…”
Get full text

Efficacy and prognostic factors of anti-PD1 and nivolumab-ipilimumab therapy in advanced melanoma patients resistant to prior ICI treatment by Caner Acar, Haydar Çağatay Yüksel, Gökhan Şahin, Fatma Pinar Açar, Salih Tünbekici, Gülçin Çelebi, Burçak Karaca

Subjects: “…Advanced melanoma…”
Get full text

Acquired lipodystrophy following use of pembrolizumab by Maya Weitzen, Marcus DaSilva Goncalves, Shaheer Khan, Alexander Barbaro, Richard Carvajal, Keyur Thakar

Subjects: Get full text

Efficacy and safety of PD‐1 monoclonal antibody combined with interferon‐alpha 1b and anlotinib hydrochloride as the second‐line therapy in patients with unresectable advanced mela... by Bolun Zhao, Mengyu Zhang, Jingyi Tang, Daopei Zou, Fang Liu, Qiong Shi, Tianwen Gao, Chunying Li, Guannan Zhu

Subjects: “…advanced melanoma…”
Get full text

INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia by Mouna Jameleddine, Nabil Harzallah, Hela Grati, Marie Christine Odabachian Jebali, Jaafar Chemli, Sebastián García Martí, Natalie Soto, Andrés Pichon-Riviere, Chokri Hamouda

Subjects: Get full text

Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression‐free survival based on reconstructed individual patient data by Andrea Ossato, Vera Damuzzo, Paolo Baldo, Daniele Mengato, Marco Chiumente, Andrea Messori

Subjects: “…advanced melanoma…”
Get full text

Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients by Stéphane Dalle, Estelle Verronese, Axelle N’Kodia, Christine Bardin, Céline Rodriguez, Thibault Andrieu, Anais Eberhardt, Gabriel Chemin, Uzma Hasan, Myrtille Le-Bouar, Julie Caramel, Mona Amini-Adle, Nathalie Bendriss-Vermare, Bertrand Dubois, Christophe Caux, Christine Ménétrier-Caux

Subjects: “…Advanced melanoma…”
Get full text